 Home > Active Ingredient News > Antitumor Therapy > Eur J Cancer: Adjuvant radiotherapy after radical resection can significantly improve the prognosis of patients with extrahepatic cholangiocarcinoma!

Eur J Cancer: Adjuvant radiotherapy after radical resection can significantly improve the prognosis of patients with extrahepatic cholangiocarcinoma!

 Last Update: 2021-09-12
 Source: Internet
 Author: User

Tags

positive negative controls

psma prostate cancer

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Cholangiocarcinoma is a relatively rare malignant tumor that originates from the bile duct epithelium and has a poor prognosis

This study aims to evaluate the effect of adjuvant radiotherapy (RT) after radical surgery on the prognosis of EHBD patients

Between January 2000 and December 2015, a total of 1475 EHBD patients who underwent radical surgery were recruited

Local recurrence-free survival of the two groups of patients

The median age of the tested patients was 67 years old

The RT-positive group had more proximal tumors, advanced tumors, lymph node metastasis, peripheral infiltration, and resection margin involvement than the RT-negative group.

Overall survival of the two groups of patients

After a median follow-up of 36 months, 211 cases of local recurrence, 307 cases of distant metastasis and 322 cases of local recurrence combined with distant metastasis occurred

Auxiliary RT is related to prolonged overall survival Auxiliary RT is related to prolonged overall survival

In summary, adjuvant radiotherapy combined with chemotherapy can improve the survival and prognosis of patients with EHBD who have undergone surgery

Adjuvant radiotherapy combined with chemotherapy can improve the survival prognosis of patients with surgically resected EHBD Adjuvant radiotherapy combined with chemotherapy can improve the survival prognosis of surgically resected EHBD patients

Original source:

Kim Kyubo,Yu Jung Il,Jung Wonguen et al.

Role of adjuvant radiotherapy in extrahepatic bile duct cancer: A multicenter retrospective study (Korean Radiation Oncology Group 18-14

in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

N-Desmethyl Imatinib 99%

CAS No.: 404844-02-6

Pharma Grade

$1/MT FOB

Topotecan HCl CAS 119413-54-6 for Scientific Research Chemical Reagents Use only topetecan hydrochloride

CAS No.: 119413-54-6

Pharmacy Grade

$4-5/G FOB

Regorafenib 98% white powder 755037-03-7 Regorafenib (BAY 73-4506)

CAS No.: 755037-03-7

Pharmacy Grade

$4-5/G FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.